Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial

Overactive Bladder Clinical Trial

Official title:

Prospective, Multi-Center, Randomized, Double-Blinded Trial of Percutaneous Tibial Nerve Stimulation With the Bioness StimRouter Neuromodulation System Versus Sham in the Treatment of Overactive Bladder (OAB)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02873312
• Other study ID #: CP-STMR-OAB-002
• Status: Recruiting
• Phase: N/A
• Start date: February 10, 2017
• Est. completion date: July 30, 2021

Study information

• Verified date: July 2020
• Source: Bioness Inc
• Contact: Cathy Madrid, CRA
• Phone: 6617144595
• Email: cathy.madrid[@]bioness.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Approximately 20 Study Sites will participate over total 24 months. Study population will consist of adults age 22 or over, reporting overactive bladder (OAB) symptoms for at least 3 months. Primary Study Objectives: 1. To assess efficacy of the StimRouter stimulation in improving OAB symptoms of urgency and frequency as measured by Patient Voiding Diary when targeting the posterior tibial nerve 2. To assess safety of the StimRouter therapy for the indication of OAB Secondary Study Objective: To evaluate efficacy of the StimRouter therapy in addressing urinary urge incontinence as measured by the Patient Voiding Diary Study Design is prospective, multi-center, randomized, double-blinded Primary Endpoint: The primary efficacy endpoint will be the difference between the investigational and control groups in proportion of responders, where Responder is defined as having ≥50% improvement in average voiding frequency above the normal value of 8 (those returning to normal voiding based on 7-day average voids/leak episodes < 9, will be categorized as achieving half or more reduction) AND having ≥50% improvement in average number of moderate to severe urgency episodes, at approximately three months after programming. Secondary Endpoint: Secondary endpoint will be the difference between the investigational and control groups in proportion of patients with reduction by half or more in urinary urge incontinence as measured by the average number of urge incontinence episodes per day.

Description:

Approximately 180 subjects will be enrolled in the Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder study. After signing the informed consent and completing the screening visit, eligible candidates will be asked to (1) stop any OAB medications (including but not limited to anti-muscarinic medication or tricyclic antidepressants (TCA) as well as stabilize dosage and frequency of any concomitant medications for 3 weeks, if applicable, and then (2) complete a daily Patient Voiding Diary for 7 days . Subjects will then return to the office for baseline review. If all screening and baseline criteria are met, the subject will be enrolled, randomized in a 1:1 ratio into either the "control group" or the "investigational group" and scheduled for implant with the StimRouter device. After approximately 3 weeks for healing post-implant, study participants will be programmed according to their randomization assignment. All subjects will be instructed to apply stimulation at least 3 days/week for at least 30 minutes/day (i.e., the minimum protocol requirements for device use) for 6 months and to apply stimulation when they anticipate OAB events. Patient Voiding Diaries will be completed by the participants for 7 days prior to each follow-up visit and provided to the office at each follow-up visit. Follow-up visits will occur at Month 1, Month 2, Month 3, Month 5 and Month 6. Each follow-up visit will include the review of subject voiding diaries and the completion of other subject questionnaires for measuring OAB and quality of life assessments. Final follow-up evaluations for all subjects will occur at Month 6.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: July 30, 2021
• Est. primary completion date: July 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

1. Male or female age =22 years and competent to provide consent

2. Minimum 3 months of self-reported OAB symptoms

3. A mean score of =4.0 on the OAB-q symptom questions 1-8

4. Diagnosis of OAB with Overactive Bladder Symptom Score (OABSS) = 8.0

5. Average urinary frequency of = 10 daily voids associated with urgency

6. Able to tolerate and sense tibial nerve stimulation

7. Willing to discontinue OAB and/or tricyclic antidepressant (TCA) medications for 3 weeks prior to the implant and for the entire study period and not to change dosages/frequency of all others for 3 weeks prior to the implant

8. Failed/inadequate response to first- and second-line therapy for OAB

9. Body mass index (BMI) < 31 or investigator does not expect BMI to interfere with ability to place the implant or negatively impact healing at implant site

10. Able to toilet self and have and maintain good personal hygiene

11. Able to utilize the StimRouter system independently

12. Negative urine dipstick result (no UTI detected)

13. If female of child-bearing age, willing to use a medically-acceptable method of contraception for the duration of the study (e.g. oral contraceptives, condoms, shot, patch, etc.)

14. Able to provide clear, thoughtful responses to questions and questionnaires

15. Willing to visit office for device programming and clinical evaluations at 1, 2, 3, 5 and 6 months after starting external device usage

16. Willing to complete a Patient Voiding Diary for 7 consecutive days prior to implant and 7 consecutive days before each follow-up visit, with moderate to severe urge component at Baseline

Exclusion Criteria:

1. Neurogenic bladder

2. Urinary tract mechanical obstruction including but not limited to Benign Prostatic Hyperplasia (BPH), treated or untreated, with ongoing significant obstruction

3. Treatment of bladder or pelvic floor dysfunction with botulinum toxin (Botox ®) or surgery in past 12 months

4. Urinary tract, bladder or vaginal infection or inflammation

5. More than minimal level of stress incontinence or mixed incontinence with stress component likely to confound study outcome

6. Type I diabetes or uncontrolled Type II diabetes

7. Allergy to local anesthetic or adhesives

8. Bleeding disorder or on an anticoagulant that cannot be stopped for 3 days before the implant

9. Pregnant, lactating, planning to become pregnant, given birth in the past 12 months, or female of child-bearing potential and not practicing a medically-approved method of birth control

10. Skin lesions or compromised skin at the implant or stimulation site

11. Use of investigational drug or device therapy or participation in any study involving or impacting gynecologic, urinary or renal function within past 4 weeks

12. Implanted neurostimulator, pacemaker, or defibrillator

13. Current use of TENS in pelvic region, back or leg

14. Current or prior use of electrical stimulation therapy for OAB (e.g. PTNS, sacral nerve stimulation, pelvic floor muscle stimulation or biofeedback)

15. Metallic implant below knee, within 6 inches of proposed site for implanted lead

16. Prior vaginal mesh or similar surgery that has not abolished stress incontinence, intravaginal pessaries, or other evidence of stress incontinence significant enough to confound study

17. Requirement for serial MRIs

18. Presence of a documented condition or abnormality that could compromise the safety of the patient

19. Life expectancy of less than 1 year

Related Conditions & MeSH terms

• Overactive Bladder
• Urinary Bladder, Overactive

Intervention

Device:
• StimRouter
The StimRouter System is a neuromodulation system consisting of the following components and accessories: An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead. An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories. A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories.

Locations

Country	Name	City	State
Canada	Northern Alberta Urology Center	Edmonton	Alberta
Canada	University of Sherbrooke	Sherbrooke	Quebec
Canada	Toronto Western Hospital	Toronto	Ontario
Canada	Silverado Research, Inc	Victoria	British Columbia
United States	Comprehensive Urologic Care	Barrington	Illinois
United States	University of North Carolina Urogynecology	Chapel Hill	North Carolina
United States	Cleveland Clinic Glickman Urologic and Kidney Institute	Cleveland	Ohio
United States	Barrett Cowan, MD, Urology Associates	Englewood	Colorado
United States	Michael England, MD, Texas Health Care	Fort Worth	Texas
United States	Michael DeBakey VA Med Ctr	Houston	Texas
United States	Kaiser Permanente Reserach	Irvine	California
United States	Sheldon Freedman, MD LTD	Las Vegas	Nevada
United States	University of Southern California	Los Angeles	California
United States	Basel Hassoun	Oklahoma City	Oklahoma
United States	Clinical Research Center of Florida	Pompano Beach	Florida
United States	Providence St. John's Health Center	Santa Monica	California
United States	Meridian Clinical Research, LLC/Urology Associates Savannah	Savannah	Georgia
United States	Skyline Urology	Sherman Oaks	California
United States	Del Sol Research	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Bioness Inc

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1) Patient Voiding Diary	The daily Patient Voiding Diary is a self-reported record and it includes how frequently the patient intentionally urinates during the day (frequency) and is awakened to urinate at night (nighttime void frequency), amount voided, number of urgency episodes, voids with moderate to severe urgency, urinary urge incontinence episodes and the degree of urgency to urinate. The 7-day daily Patient Voiding Diary will be assessed at baseline and at approximately 3 months after programming to measure total number of voids (frequency) and voids with moderate-to-severe urgency.The average for each of the seven-day periods will be calculated and compared.	Baseline, Month 3
Primary	Adverse Events reported cumulatively throughout study	Occurrence of anticipated and unanticipated adverse events will be documented, accumulated and reported for the duration of the study	Baseline through Month 6
Secondary	Seven-Day Patient Voiding Diary	The 7-day daily Patient Voiding Diary will be assessed at baseline and at approximately 3 months after programming to measure urinary urge incontinence episodes.	Baseline, Month 3